[ASCO 2024] 옵디보+여보이, 마침내 간세포암 1차 치료 정복

의약뉴스 2024-06-06 21:57:03

삭제하기

연구의 1차 평가변수는 OS로 목표를 달성했고, PFS는 탐색적 분석 대상이었습니다.

의약뉴스 2024-06-06 21:47:57

삭제하기

With Opdivo-Yervoy combo, Bristol Myers calls Roche and AstraZeneca's bets in first-line liver cancer

Bristol Myers Squibb's Opdivo and Yervoy helped 38% of patients with newly diagnosed liver cancer live past three years in a phase 3 trial, setting a new record.

의약뉴스 2024-06-06 21:20:58

삭제하기

Median progression-free survival was similar between the arms at 9.1 months with nivolumab plus ipilimumab compared with 9.2 months with lenvatinib or sorafenib. However, the progression-free survival rates were higher with the combination at 18 months (34% vs 18%) and 24 months (28% vs 12%).

“We are now offering a new standard of care,

의약뉴스 2024-06-06 21:20:09

삭제하기

he primary endpoint was overall survival (OS). Secondary endpoints included objective response rate (ORR) and duration of response (DOR) per blinded independent central review (BICR) using RECIST v1.1.

"What this study does primarily is give us 3 options to think about in the first-line setting that have all beaten the previous standard.”

김명숙 2024-06-06 16:41:06

삭제하기

통계적 유의성확보실패했는데
팩트좀알고 찾아보고 기사를써주세요.
.실패.